Certara, Inc.

As of October 31, 2025, Certara, Inc. shows a mildly bullish trend with positive momentum indicators, but has underperformed the S&P 500 recently, returning -7.67% and -11.63% over the past week and month, respectively, while year-to-date it has gained 8.45% compared to the S&P 500's 16.30%.

As of October 31, 2025, Certara, Inc. shows a mildly bullish trend overall, supported by positive momentum indicators, though there are mixed signals from the Bollinger Bands and Dow Theory.

As of October 31, 2025, Certara, Inc. shows a mildly bullish technical trend, with positive momentum indicators, but has underperformed the S&P 500 recently, raising concerns despite a year-to-date return of 9.2%.

As of October 31, 2025, Certara, Inc. shows a mildly bullish trend with positive momentum indicators, but mixed signals suggest caution, especially as it has underperformed the S&P 500 recently while outperforming it year-to-date.

As of October 10, 2025, Certara, Inc. shows a neutral technical trend with mixed indicators, outperforming the S&P 500 year-to-date but lagging over the past year, suggesting a cautious investment approach.

As of October 10, 2025, Certara, Inc. shows a neutral technical trend with mixed indicators, including bullish weekly MACD and bearish daily moving averages, while its recent performance outpaces the S&P 500 over one month but lags over one year, suggesting a cautious investment approach.

As of October 10, 2025, Certara, Inc. shows a neutral technical stance with mixed signals, as the weekly trend is sideways despite a strong 1-month return of 15.71%, while its 1-year performance lags behind the S&P 500.

As of October 3, 2025, Certara, Inc. shows a mildly bullish technical trend supported by positive MACD and Bollinger Bands, despite some caution from daily moving averages.

As of October 3, 2025, Certara, Inc. shows a mildly bullish technical trend supported by positive weekly and monthly indicators, outperforming the S&P 500 in various time frames, despite mixed short-term signals from daily moving averages.

As of August 22, 2025, Certara, Inc. is in a mildly bearish trend, with mixed indicators showing short-term outperformance against the S&P 500 but long-term underperformance.

As of August 6, 2025, Certara, Inc. is considered undervalued with a PEG ratio of 0.63 and a high P/E ratio of 170, despite underperforming the S&P 500 with a 1-year return of 7.87%.

As of November 8, 2023, Certara, Inc. is considered overvalued with a high P/E ratio of 170, significantly exceeding industry averages, and has underperformed the S&P 500 with a 1-year return of -23.31%.

As of June 17, 2025, the technical outlook is mildly bearish due to negative weekly indicators like MACD, RSI, and Bollinger Bands, despite a mildly bullish daily stance and contrasting monthly perspective.

Certara, Inc. is a small-cap software company specializing in drug development and regulatory science, with recent net sales of $106 million and a net profit of $5 million. It has a market cap of approximately $1.71 billion, a P/E ratio of 170, and a debt-to-equity ratio of 0.11.

As of Jun 18, Certara, Inc. has a market capitalization of 1,714.81 million, with net sales of 394.49 million and a net profit of -2.62 million over the latest four quarters.